iLite Insulin Assay Ready Cells

iLite Insulin Assay Ready Cells Developed and Manufactured by Svar Life Science

The Eagle Biosciences iLite Insulin Assay Ready Cells are intended for:

• Quantification of Insulin
• Determination of neutralizing antibodies against Insulin

Content: >250 µL vial of Assay Ready Cells suspended in RPMI 1640 with 20% heat inactivated fetal bovine serum (FBS), mixed 1:1 with cryoprotective medium.
Receipt and Storage: Upon receipt confirm that adequate dry-ice is present, and the cells are frozen. Immediately transfer to -80°C storage. Cells should be stored at -80°C (do not store at any other temperature) and are stable as supplied until the expiry date shown. Cells should be used within 30 min of thawing and should be diluted immediately after thawing.
For Research Use Only

---

Key benefits of iLite® Assays

• Highly specific reporter gene cell lines
• Very sensitive cell line responses (>10 fold inductions)
• Assay Ready Cells – ready-to-use from the freezer, without culturing of cells
• Assays within a workday (typically 4-7 hour assays)
• Normalization gene, which eliminates unwanted matrix effects

---

Product Description

iLite® Insulin ARCs are avian DT-40 cells (ATCC#CRL211) which has been genetically engineered to be responsive to Insulin, resulting in the specific expression of Firefly Luciferase. Normalization of cell counts and serum matrix effects is obtained by a second reporter gene, a Renilla Luciferase reporter gene construct, under control of a constitutive promotor.

---

Application

The iLite® Insulin ARCs can be used to quantify insulin activity in human serum (without interference from factors present in human serum including IGF-1) and for quantification of the activity of neutralizing anti-Insulin antibodies. Application Notes for the following assays are available:
• Quantification of Insulin activity (LABEL-DOC-0389)
• Determination of neutralizing antibodies against Insulin (LABELDOC-0390)

---

Products Related to Insulin Assay Ready Cells

Insulin ELISA Assay Kit
Insulin Ultrasensitive ELISA Kit
iLite FGF-21 Assay Ready Cells

EagleBio的5α-雄甾烷-3α，17β-二醇葡糖醛酸化物是C19类固醇，缩写为3α-DiolG，5α二醇G或简称为α二醇G。它主要作为睾丸激素和二氢睾丸激素（DHT）的代谢产物生产。它主要在目标外围组织（例如皮肤）中产生，尤其是在毛囊周围。大量的3α-DiolG刺激会导致过多的头发形成，特别是在女性通常不存在头发的地方。近年来，在研究患有特发性多毛症的妇女的临床研究人员中，人们对这种类固醇的测量越来越感兴趣。已知是3α-DiolG前体的类固醇包括脱氢表雄酮（DHEA），硫酸脱氢表雄酮（DHEAS），二氢睾丸酮（DHT），雄烯二酮和睾丸激素。已显示只有3α-DiolG随多毛症增加而随治疗减少。这种相关性在多囊卵巢综合征（PCO）患者中也得到了证明。3α-DiolG的测定因此被证明是多种方式的有用指标，包括监测特发性多毛症和PCO妇女的治疗进展。此外，接受环孢霉素A治疗的糖尿病患者（无论男女）均显示3α-DiolG水平升高，这种副作用导致以前无毛的区域出现了头发。3α-DiolG的测定因此被证明是多种方式的有用指标，包括监测特发性多毛症和PCO妇女的治疗进展。此外，接受环孢霉素A治疗的糖尿病患者（无论男女）均显示3α-DiolG水平升高，这种副作用导致以前无毛的区域出现了头发。3α-DiolG的测定因此被证明是多种方式的有用指标，包括监测特发性多毛症和PCO妇女的治疗进展。此外，接受环孢霉素A治疗的糖尿病患者（无论男女）均显示3α-DiolG水平升高，这种副作用导致以前无毛的区域出现了头发。